Life Sciences Archive » June, 2012

Life Sciences - June, 2012

261 articles

• Roche To Pay $18M Damages In Accutane Suit
• Care Providers Wary Of States Bucking Medicaid Expansion
• J&J Can't Shake False Ad Suit Over Bedtime Bath Products
• Device Cos. Face Slim Chance Of Tax Repeal After ACA Ruling
• HHS Unveils New Grants To Build State-Based Exchanges
• Acid Reflux Device Maker Beats Class Cert. In Row Over Ads
• Varian Again Loses Bid To Nix Pitt X-Ray Patent Ruling
• Law360's Global 20 Firms Open Up New Frontiers
• Endo Sues Noven To Protect The Market For Lidoderm
• Supreme Court Seeks SG's View In Claim Construction Case
• FDA Warns GSK's Zofran May Cause Abnormal Heart Rhythm
• With Ruling In Hand, Supreme Court Nixes ACA Challenges
• GSK, Human Genome Escalate $2.6B Buyout Battle
• Q&A With Katten's Robert Breisblatt
• Icahn Sues Forest Labs For Docs In Renewed Proxy Fight
• Christopher V. SmithKline: Impact On Pharma — And Beyond
• ACA Ruling Heats Up Already-Hopping Health Deals Scene
• Texas Insurance Exchange Debate Looms As ACA Upheld
• FDA Panel Calls For More Warnings On Metal Hip Implants
• 3rd Circ. Revives Suit Against GSK Over Avandia Injury Costs
• Calif. Dems Hail ACA Ruling While GOP Urges Caution
• In ACA Ruling, A Warning Not To Read High Court Tea Leaves
• Roberts Swing Vote On ACA Strikes A Conservative Balance
• Dissecting The Supreme Court Ruling On Health Care Reform
• BioSante Sued Again Over Female Libido Drug Disappointment
• Cuomo Hails High Court Health Ruling As NY GOPs Fume
• Pfizer Avoids Off-Label Marketing Suit Over Geodon, Zyvox
• Generic-Drug Users Can't Pin Brand-Name Cos., NJ Court Says
• GOP Vows Health Law Repeal, But Chances Are Slim For Now
• Ex-McDermott Atty Gets Theranos Trade Secrets Suit Trimmed
• Q&A With Seyfarth's Michel Feldman
• Health Care Ruling Brings Contract, Grant Opportunities
• High Court Limits On Medicaid Expansion May Be Moot
• Health Care Ruling Is Mixed Blessing For Insurers
• ACA Ruling To Spark More Investment In New Care Models
• Getting To A Rule For Reverse Payments
• Covidien Sales Reps' OT Suit Nixed By High Court GSK Ruling
• State Laggards Face Health Exchange Dilemma
• Biosimilars Dodge Bullet As High Court Upholds ACA
• With ACA Affirmed, Employers Must Prepare For 2014
• High Court Upholds Health Care Law Under Taxing Powers
• DePuy, Others Urge FDA Not To Lump Together Hip Implants
• Sandoz Takes Aim At Ranbaxy's Generic Nexium Sales Rights
• Firms Rev Up To Weigh In After Health Care Decision
• FDA Says Amylin Hid Diabetes Drug Safety Data
• Arena's Belviq 1st Obesity Drug To Get FDA's Nod Since 1999
• FDA Moves Forward On Study Of Drug Ad Offers
• USPTO Official Slams Use Of Compulsory Patent Licenses
• Q&A With Sills Cummis' Lori Waldron
• Ivera Expands IV Cap Patent War Against Hospira, Others
• Cumberland Tries To Shut Down Sagent's Generic Acetadote
• Expert Networking Exec Cops To Illegal Abaxis Tips
• FDA User Fee Bill Breezes Through Congress
• Amylin Board Hid $3.5B Offer To Buy Cheap Options: Suit
• Obama Vows Veto For Spending Bill That Shorts FDA By $700M
• Public Citizen Pushes FDA To Deny Diet Pill Approval
• W.Va. AG Sues 14 Drug Distributors Tied To Painkiller Abuse
• FDA Rips Covidien Response To Surgery Device Safety Issues
• Q&A With Dechert's George Gordon
• House GOP Targets AARP's Role In Health Care Reform Law
• The Role Of IP In Medical Device Investments
• Post-Mensing Landscape A Wasteland For Plaintiffs
• Bristol, Sanofi Sued Over Allegedly Deceptive Plavix Marketing
• Pfizer Sues 11 Rivals To Defend Pristiq Patent
• Mylan, Sandoz Infringed Teva's MS Drug Patents, Judge Finds
• Merck Pays $10M To Exit ERISA Class Action Over Vytorin
• $70M Novo Nordisk OT Suit Killed By High Court GSK Ruling
• Merck Hit With Antitrust Class Action Over Vaccine Data
• Metal Hip Implant Safety Studies Lacking, FDA Says
• FDA Again Delays Approval Of Pfizer-BMS Anti-Clotting Drug
• Medtronic Owes $7M In Device Royalties, University Says
• Q&A With Covington's Gerald Masoudi
• Justices Ask SG To Weigh In On GSK, Classen Patent Row
• Section 102: A Dead Letter For Qualifying Claims
• High Court Will Consider Medicare Repayment Deadlines
• High Court's Health Care Decision Expected Thursday
• Wis. High Court Upholds $13.5M Award Against Pfizer Unit
• Generics Cos. Escape From Darvocet, Darvon MDL
• FDA Tells Watson, Swedish Drugmaker To Pull Misleading Ads
• Smith & Nephew Says Sales Contractors Broke Noncompete
• GCs Name Law Firms With Top Shelf Brands
• FDA Hit With FOIA Suit Seeking Livestock Antibiotics Data
• Q&A With Oblon Spivak's Dan Pereira
• In Texas, The Learned Intermediary Doctrine Holds Steady
• Medical Device Cos. WL Gore, Cook Sued Over Stent Patents
• Allergan Requests Appeal Of Del. Botox Decision
• Abbott Can't Shake Roxane's Suit Over Generic Norvir
• FDA Supplement Guidance Likely To Remain Onerous, Attys Say
• Roche Ignored Drug Safety Reports, EU Watchdog Says
• Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
• Whistleblowers Say Merck Falsified Mumps Vaccine Data
• Email Monitoring Can Be Illegal, OSC Tells Federal Agencies
• FDA To Lower Risk Category For Hemodialysis Devices
• FDIC Says Forged Inyx Docs Support $25M Westernbank Claim
• Determining A Product's Defect By Its Primary Use
• EU Data Protection — Implications For Clinical Studies
• Q&A With Foley & Lardner's Antoinette Konski
• Medtronic Trumps Gore's Stent Graft Patent Claims
• J&J Can't Get New Trial Over $1.2B Ark. Risperdal Fine
• GOP Moves To Block IRS Premium Tax Credit Rule
• Joint Ventures In China: What Every CEO Should Know
• Merck Accused Of Using 'Madagascar 3' To Illegally Target Kids
• FDA Panel Endorses Onyx Pharmaceuticals' Blood Cancer Drug
• FDA User Fee Bill Keeps Rocketing Through Congress
• Buchanan Injects Health Team With Pair Of Shareholders
• Q&A With Roetzel's Michael Keller
• Boston Scientific Stents Again Beat J&J Infringement Claims
• FDA Panel Won't Back Sanofi Blood Thinner For Cancer Patients
• Drugmakers Find Much To Love In Final FDA Reform Bill
• Disbarred Attys Must Forfeit Assets Over Fen-Phen Fees
• Drug Rep Ruling May Give Employers More Ammo In OT Suits
• Pfizer Storing Up $330M To Settle Menopause Drug Suits
• Union Health Plan Sues Merck Over Drug Copay Subsidies
• Judge Certifies Limited Class In Flonase Antitrust Action
• Sens. Pressure High Court To Televise Health Law Decision
• Biz Leaders Urge Cool-Off Period After Health Care Ruling
• USPTO Says Novartis' Patent Term Case Is Time-Barred
• Q&A With Drinker Biddle's Jesse Witten
• GE Says Cybersquatting Ultrasound Dealer Infringes Marks
• Tackling A Circuit Splitter: Amgen In The High Court
• 'Regulation By Amicus' No Longer An Option For Agencies
• Myriad, ACLU Argue Over Prometheus In Gene Patent Battle
• US Defends Pharmacy Price Caps For Vets To DC Circ.
• Industry-Backed Drug Tracking System Gone From FDA Bill
• Drug Theft, Counterfeiting Bills Would Garner Few Cases: CBO
• EU Breast Implant Study Won't Help Litigation Targets
• Novartis, Others Win $400M In HHS Vaccine Center Contracts
• Q&A With Arnold & Porter's Dan Kracov
• Proskauer Keeps Grip On Client Docs In $20M Malpractice Suit
• High Court Deems GSK Drug Sales Reps OT-Exempt
• FDA Probe Could Grow To Encompass Fresenius Empire
• Apotex Did Not Infringe On Merck's Nasonex Patent: Judge
• Wyeth Can't Kick Class Cert. In Canadian Suit Over Premarin
• Head Of ACA Implementation To Step Down From Post
• K&L Gates Adds Product Liability Team In Orange County
• Statehouse The Place To Tackle AG Fee Deals, Experts Say
• Q&A With Fulbright's Lana Varney
• Skadden Steers Valeant To $312M Deal For Oral Care Co.
• Janssen Sues Mylan, Others To Block Generic Prezista
• St. Jude Stock Flatlined Amid Recalls, Investors Say
• Health Care Ruling Could Mean Years Of Delay For Biosimilars
• Fed. Circ. Won't Rethink Standing In Myriad Gene Patent Case
• Sens. Pass $159B Bill Sans NLRB, ACA Defunding Measures
• Fed. Circ. Makes It Harder To Prove Willful Infringement
• EU Lawmakers Push For Tougher Breast Implant Standards
• Merck Wins Dismissal Of Vioxx False Claims Suit From MDL
• Ceragenix Whistleblower's Malpractice Suit Shut Down
• FDA Panel Backs Edwards Heart Valve For Wider Use
• Biotronik Tangles With St. Jude Over Sales Rep Noncompete
• Q&A With Drinker Biddle's Robyn Shapiro
• Lights, Camera, Courtroom: Lessons From Mike Wallace
• Novartis Defeats Appeal To Bone Drug Bellwether Ruling
• Pfizer Battles 2nd FCA Suit Over Antifungal Drug Promotions
• Firm Sued Over Fees To Preempt Malpractice Claims: Lab Co.
• Univ. of Utah's RNA Patent Suit Survives Challenge
• Report Fingers 2nd St. Jude Device For In-Body Wire Failure
• GSK Says ERISA Suit Dismissal Backed By 6th Circ. Ruling
• Wolf Greenfield Lands IP Pros From Kirkland, WilmerHale
• Q&A With Katten's Brian Sodikoff
• Payors Urge 1st Circ. To Revive Pfizer Neurontin MDL Claims
• Upsher-Smith To Pay £223M For UK Drug Co. Proximagen
• Another Approach To The Unsafe Product Exclusion
• CVS, Rite Aid Latest To Sue Wyeth, Teva Over Effexor
• Panel OKs Bill To Align Calif. False Claims Law With US Law
• $159B Bill Advances Over GOP Protests Of ACA Funding
• China's Compulsory License Rule Has Drug Cos. On Edge
• High Court's Amgen Ruling Could Stymie Securities Classes
• Lilly Adds $20M To Investment In Chinese Drugmaker
• NY Enlists Docs, Pharmacists In Rx Drug Crackdown
• FTC Blasts Androgel Pay-For-Delay Ruling In 11th Circ.
• Novartis Asks 4th Circ. To Block $1M Aredia, Zometa Verdict
• Troutman Adds McDermott Life Sciences IP Quartet In NY
• GSK To Hand Over $227M For Basilea Eczema Drug
• FSMA's Potential Impact, Part 2: Title And Risk Of Loss
• Q&A With Axinn Veltrop's Jeremy Lowe
• ACLU Defends Standing Of Lone Gene Patent Plaintiff
• RyMed Wins Catheter Row After USPTO Nixes Rival's Patent
• Edwards Valve Comparable To Traditional Surgery, FDA Says
• J&J Dumps Wrist Device IP To Clear Way For $21B Synthes Buy
• Cooley Adds Partner To Growing Shanghai Office
• Allergan Can't Kick Investor Suit Over $600M Botox Settlement
• Savient Denies Default In Countersuit Against Creditor
• Greenberg Adds Health Dealmaker To Orange County Office
• Q&A With Akin Gump's Mark Mansour
• FDA Warnings Can Be Fought In Court, Supreme Court Told
• Hospitals Call For Drug Shortage Fines In FDA Bill
• High Court To Weigh In On Amgen Class Cert. Quarrel
• J&J Announces $600M Hit To Pay For Drug Settlements
• Texas High Court Adopts Intermediary Rule In Drug Cases
• Struggling Savient Swipes Creditors' Bid To Appoint Receiver
• FDA Mulls Stricter Controls To Curb Hydrocodone Abuse
• Feds Ignore Lessons Of GSK Obstruction Case, Attys Say
• GOP Says Obama Aides Helped Run ACA Ad Campaigns
• Genentech, UPenn End Herceptin Patent Row On Eve Of Trial
• Gilead Stalled On HIV Prevention Approval For Truvada
• Sens. Call For Tighter Reins On Prescription Painkillers
• Mylan, Teva Settle Over Generic Provigil Market Rights
• Q&A With Debevoise's Kevin Rinker
• GSK Extends $2.6B Offer For Human Genome
• Generics Industry Pushes Congress On Brand-Name Samples
• CR Bard Picks Up Bellwether Win In Vein Filter Defect Suit
• Device Tax Repeal Previews Fight Over Health Law Deals
• Medicis Sues To Block Zydus' Generic Acne Treatment
• Abbott Asks Calif. Judge To Toss B&L Suit Over Noncompetes
• Orthofix To Pay $42M To End Kickback, Medicare Fraud Claims
• Pfizer Begins Spinoff Of Animal Health Business
• Q&A With Robins Kaplan's Jake Holdreith
• Connecting Off-Label Marketing To Use: Not Quite A To B
• Lawmakers Train Fire On VA's Drug Acquisition Practices
• FCC Chief Targets Barriers To Wireless Medical Technology
• Obama May Veto Threat To PPACA's Health Device Tax
• 6th Circ. Lets Novartis Off Hook In Bone Drug Liability Suit
• Doctors Don't Properly Store Kids' Vaccines, HHS Says
• Woman-Owned Firm Scharf Makes Independent Debut
• Masimo Says Indian Medical Device Co. Misled TED Audience
• High Court Health Ruling Won't Transform System, Execs Say
• Stryker Offers $33M To End DOJ Probe Into Knee Product
• FDA Must Strengthen Reviews For Risky Devices: FDA Head
• Quinn Emanuel Brings On Jones Day Pharma Patent Trio
• Q&A With Morgan Lewis' Steve Mahinka
• Tripping Up Defendants With Bootstrap Reasoning
• Mich. Courts Can't Nix Policy Limits Automatically: 6th Circ.
• Merck Targets Sandoz, Intas Over Generic Emend Plans
• For Biosimilars, Profit's All In A Name
• FDA Warns Siemens Over Biochemical Device Design
• 9th Circ. Voices Doubt On $60M NuVasive Trademark Award
• Kardashians Say They Aren't At Fault For False Diet Pill Ads
• J&J Tells Judge It Will Stop Selling Vaginal Implants
• FDA Must Act On Livestock Antibiotics, Judge Says
• FDA Should Boost Training For Device Reviewers: Report
• GE Healthcare Grabs Brazilian X-Ray Systems Maker
• 3rd Circ. Strips Hospitals Of Standing In Becton Antitrust Suit
• Pfizer Boosts Quigley Asbestos Funds In New Ch. 11 Plan
• Nelson Mullins Snags Health Care Partner From Pillsbury
• For Whom The Court Tolls
• Q&A With Baker Botts' Sandra Lee
• 8th Circ. Reinstates Investors' Claims Against KV Pharma
• Jury Clears J&J In Rembrandt Contact Lens Patent Row
• Smith & Nephew Hip Problems May Persist Beyond Recall
• Hogan Bolsters Health Practice With Capitol Hill Vet
• Health Groups Want Deadline For Long-Stalled Device Rules
• Greenberg Grabs International M&A Atty for Philly Office
• Judge Trims $421M Medicaid Kickback Suit Against Organon
• Abbott Targets Kremers Over Niaspan Clone
• Q&A With O'Melveny's David Deaton
• Judge Could Deal Out Fines In Vitamin C Antitrust MDL
• 8 Trends In Venture Capital 2012
• Pfizer, Monsanto Lose Bid For Contributions To $600M Cleanup
• Legal Considerations For mHealth Stakeholders
• Ceragenix Atty Sued Over Whistleblower's Ouster
• Drug Promoters Say Genentech Shorted Them On OT
• FDA Warns Of Harmful Unlisted Drugs In Mexican Supplement
• Judge Grants New Trial In $212M Allergan Botox Suit
• Pharmacists Urge Congress Not To Restrict Hydrocodone Use
• 8th Circ. Absolves Drugmakers In Mirapex Liability Suit
• Masimo Hit With IP Suit Over Blood-Testing Technology
• Graceway Trustee Slams Distributor's Bid To Cut Debt
• J&J Wins Reversal Of Expert Restriction In Pelvic Mesh Suits
• Pharmacists Ask FDA For Biosimilar Substitution Power
• Judge Upholds PharmAthene-SIGA Smallpox Drug Profit Share
• Q&A With Cravath's David Greenwald